טוען...
Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody
AIM: Anti‐tumour necrosis factor (TNF)‐α drugs are effective treatments for the management of moderate/severe Crohn's disease (CD), but treatment failure is common. In the treatment of paediatric CD, there are no data about the use of a third introduced subcutaneous TNF antibody golimumab. METH...
שמור ב:
| הוצא לאור ב: | Acta Paediatr |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891654/ https://ncbi.nlm.nih.gov/pubmed/32781480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apa.15522 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|